Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.

Genotyping patients for CYP2C9 and VKORC1 polymorphisms can improve the accuracy of dosing during the initiation of anticoagulation with vitamin K antagonists (coumarin derivatives). The anticipated degree of improvement in the safety of anticoagulation with coumarins through genotyping may vary depending on the quality of patient care, which varies both with and among countries. The management and the cost of anticoagulant care can therefore influence the cost-effectiveness of genotyping within any given country. In this article, we provide an overview of the cost-effectiveness of pharmacogenetics-guided dosing of coumarin derivatives. We describe the organization of anticoagulant care in the UK, Sweden, The Netherlands, Greece, Germany and Austria, where a genotype-guided dosing algorithm is currently being investigated as part of the EU-PACT trial. We also explore the costs of anticoagulant care for the treatment of atrial fibrillation in these countries.

[1]  A. Térent,et al.  Hemorrhage after Ischemic Stroke – Relation to Age and Previous Hemorrhage in a Nationwide Cohort of 58 868 Patients , 2013, International journal of stroke : official journal of the International Stroke Society.

[2]  A. Abdelhafiz,et al.  Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis. , 2012, Age and ageing.

[3]  P. Kirchhof,et al.  [Patients suffering from atrial fibrillation in Germany. Characteristics, resource consumption and costs]. , 2012, Herz.

[4]  J. You,et al.  Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation , 2012, PloS one.

[5]  G. Lip,et al.  Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation: A Report From the Swedish Atrial Fibrillation Cohort Study , 2012, Circulation.

[6]  Paul Robinson,et al.  Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation , 2012, Heart.

[7]  Juan Carlos Souto,et al.  Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data , 2012, The Lancet.

[8]  S. Åsberg.  Outcome of Stroke Prevention : Analyses Based on Data from Riks-Stroke and Other Swedish National Registers , 2012 .

[9]  B. Eliasson,et al.  Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation. , 2012, Thrombosis research.

[10]  J. Dinet,et al.  The Comparative Medical Costs of Atherothrombotic Disease in European Countries , 2012, PharmacoEconomics.

[11]  Munir Pirmohamed,et al.  Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses , 2011, BMJ : British Medical Journal.

[12]  R. P. Vermeulen,et al.  Planning and monitoring of patients for electrical cardioversion for atrial fibrillation , 2011, Netherlands Heart Journal.

[13]  J. Plumb,et al.  Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients , 2011, Thrombosis and Haemostasis.

[14]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[15]  M. Rosenqvist,et al.  Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. , 2011, European heart journal.

[16]  S. le Cessie,et al.  Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. , 2011, European heart journal.

[17]  Stirling Bryan,et al.  Cost Effectiveness of Warfarin Versus Aspirin in Patients Older Than 75 Years With Atrial Fibrillation , 2011, Stroke.

[18]  S. Behr,et al.  Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case–control study in a large population-based German database , 2011, European Journal of Clinical Pharmacology.

[19]  L. Levin,et al.  The Cost of Thromboembolic Events and their Prevention among Patients with Atrial Fibrillation. , 2011, Journal of atrial fibrillation.

[20]  B. Gage,et al.  Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation , 2010, Circulation.

[21]  J. Yfantopoulos,et al.  Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece , 2011, The European Journal of Health Economics.

[22]  Jeffrey L. Anderson,et al.  Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial , 2010, Trials.

[23]  Salim Yusuf,et al.  Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial , 2010, The Lancet.

[24]  S. Behr,et al.  Risk of intracerebral hemorrhage associated with phenprocoumon exposure: a nested case–control study in a large population‐based German database , 2010, Pharmacoepidemiology and drug safety.

[25]  J. Darbà,et al.  A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. , 2010, Pharmacogenomics.

[26]  L. Bergfeldt,et al.  Atrial fibrillation: the cost of illness in Sweden , 2010, The European Journal of Health Economics.

[27]  S. Bae,et al.  International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? , 2010, Health economics.

[28]  A. Hingorani,et al.  The effectiveness and cost-effectiveness of biomarkers for the prioritisation of patients awaiting coronary revascularisation: a systematic review and decision model. , 2010, Health technology assessment.

[29]  Marc S. Williams,et al.  A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing , 2010, PharmacoEconomics (Auckland).

[30]  A. de Boer,et al.  Pharmacogenetics of oral anticoagulant therapy. , 2010, Current pharmaceutical design.

[31]  L. Oertel,et al.  Is patient self-testing a good thing? , 2010, Journal of Thrombosis and Thrombolysis.

[32]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[33]  A. Hoes,et al.  Cost‐effectiveness of ruling out deep venous thrombosis in primary care versus care as usual , 2009, Journal of thrombosis and haemostasis : JTH.

[34]  G. Cheng,et al.  Potential Clinical and Economic Outcomes of CYP2C9 and VKORC1 Genotype‐Guided Dosing in Patients Starting Warfarin Therapy , 2009, Clinical pharmacology and therapeutics.

[35]  M. Pirmohamed,et al.  Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. , 2009, Pharmacogenomics.

[36]  P. Deloukas,et al.  Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study , 2009, Pharmacogenetics and genomics.

[37]  T. Miles,et al.  Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation. , 2009, The American journal of geriatric pharmacotherapy.

[38]  Jerry Avorn,et al.  Cost-Effectiveness of Genotype-Guided Warfarin Dosing for Patients With Atrial Fibrillation , 2009, Circulation. Cardiovascular quality and outcomes.

[39]  J. Jansson,et al.  Thrombomodulin as a marker for bleeding complications during warfarin treatment. , 2009, Archives of internal medicine.

[40]  E. E. van der Wall,et al.  Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: a prospective study of 4202 patients. , 2009, Archives of internal medicine.

[41]  Stefan N. Willich,et al.  The costs of care in atrial fibrillation and the effect of treatment modalities in Germany. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[42]  B. Gage,et al.  Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation , 2009, Annals of Internal Medicine.

[43]  H. Cohen,et al.  Self-monitoring of oral anticoagulation: does it work outside trial conditions? , 2009, Journal of Clinical Pathology.

[44]  A. Gialeraki,et al.  VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients. , 2008, Pharmacogenomics.

[45]  I. Rakovac,et al.  Self-management of oral anticoagulation reduces major outcomes in the elderly , 2008, Thrombosis and Haemostasis.

[46]  K. Souliotis,et al.  Cost-minimisation analysis of oral anticoagulant therapy monitoring methods: the case for prothrombin time self-monitoring. , 2008, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[47]  P. Talelli,et al.  In‐hospital direct cost of acute ischemic and hemorrhagic stroke in Greece , 2008, Acta neurologica Scandinavica.

[48]  H. Völler,et al.  [Update of INR-selfmonitoring]. , 2008, Hamostaseologie.

[49]  Emma Heeley,et al.  Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. , 2008, American heart journal.

[50]  Mark Crowther,et al.  Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[51]  R. Lutter,et al.  Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarin. , 2008, Personalized medicine.

[52]  S. Bryan,et al.  A multinational investigation of time and traveling costs in attending anticoagulation clinics. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[53]  Tara K. Knight,et al.  Quality of Anticoagulation Monitoring in Nonvalvular Atrial Fibrillation Patients: Comparison of Anticoagulation Clinic versus Usual Care , 2008, The Annals of pharmacotherapy.

[54]  C. Stevens,et al.  Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. , 2007, Health technology assessment.

[55]  S. Willich,et al.  The impact of atrial fibrillation on the cost of stroke: the berlin acute stroke study. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[56]  G. Nilsson,et al.  The cost of monitoring warfarin in patients with chronic atrial fibrillation in primary care in Sweden , 2007, BMC family practice.

[57]  I. Rakovac,et al.  Self-management of oral anticoagulation in the elderly: Rationale, design, baselines and oral anticoagulation control after one year of follow-up , 2007, Thrombosis and Haemostasis.

[58]  J. Jansson,et al.  Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics , 2007, Scandinavian journal of primary health care.

[59]  J. Wancata,et al.  Die Kosten von "Gehirnerkrankungen" in Österreich im Jahr 2004 , 2007, Wiener klinische Wochenschrift.

[60]  S. Willich,et al.  Anticoagulation treatment for the reduction of stroke in atrial fibrillation: a cohort study to examine the gap between guidelines and routine medical practice , 2007, Journal of Thrombosis and Thrombolysis.

[61]  J. Caro,et al.  Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM) , 2007, Journal of Thrombosis and Thrombolysis.

[62]  Resource consumption and management associated with monitoring of warfarin treatment in primary health care in Sweden , 2006, BMC family practice.

[63]  J. Struijs,et al.  Future costs of stroke in the Netherlands: The impact of stroke services , 2006, International Journal of Technology Assessment in Health Care.

[64]  B. Stricker,et al.  CYP2C9 genotyping in acenocoumarol treatment: Is it a cost‐effective addition to international normalized ratio monitoring? , 2006, Clinical pharmacology and therapeutics.

[65]  Bernhard Neundörfer,et al.  Lifetime Cost of Ischemic Stroke in Germany: Results and National Projections From a Population-Based Stroke Registry: The Erlangen Stroke Project , 2006, Stroke.

[66]  S. Iliceto,et al.  Worldwide Management of Oral Anticoagulant Therapy: the ISAM Study , 2006, Journal of Thrombosis and Thrombolysis.

[67]  D. Fitzmaurice,et al.  Self management of oral anticoagulation: randomised trial , 2005, BMJ : British Medical Journal.

[68]  E. E. van der Wall,et al.  Risks of oral anticoagulant therapy with increasing age. , 2005, Archives of internal medicine.

[69]  S. Daskalopoulou,et al.  Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. , 2005, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[70]  D. Pennell,et al.  Cardiovascular magnetic resonance of left ventricular pseudoaneurysm , 2005, Heart.

[71]  D. J. Glatz,et al.  Self-Management of oral Anticoagulation in nonvalvular Atrial Fibrillation (SMAAF study) , 2005, Zeitschrift für Kardiologie.

[72]  M. Margaglione,et al.  A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. , 2005, Blood.

[73]  G. Nilsson,et al.  Anticoagulant treatment of patients with chronic atrial fibrillation in primary health care in Sweden--a retrospective study of incidence and quality in a registered population. , 2004, Family practice.

[74]  J. You,et al.  The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy – a decision analysis , 2004, Thrombosis and Haemostasis.

[75]  B. Dijkmans,et al.  Costs of treating bleeding and perforated peptic ulcers in The Netherlands. , 2004, Journal of Rheumatology.

[76]  A. Hofman,et al.  The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon , 2004, Thrombosis and Haemostasis.

[77]  A. Abdelhafiz,et al.  Use of resources and cost implications of stroke prophylaxis with warfarin for patients with nonvalvular atrial fibrillation. , 2003, The American journal of geriatric pharmacotherapy.

[78]  F. Rosendaal,et al.  Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial. , 2003, Archives of internal medicine.

[79]  J. Ansell.  Optimizing the Efficacy and Safety of Oral Anticoagulant Therapy: High-Quality Dose Management, Anticoagulation Clinics, and Patient Self-Management , 2003, Seminars in vascular medicine.

[80]  D. Veenstra,et al.  Managed care in the genomics era: assessing the cost effectiveness of genetic tests. , 2003, The American journal of managed care.

[81]  H. Diener,et al.  Management Patterns and Health Care Use after Intracerebral Hemorrhage , 2003, Cerebrovascular Diseases.

[82]  David A Fitzmaurice,et al.  ABC of antithrombotic therapy : Bleeding risks of , 2002 .

[83]  L. Beenen,et al.  Direct Costs of Modern Treatment of Aneurysmal Subarachnoid Hemorrhage in the First Year After Diagnosis , 2002, Stroke.

[84]  A. Majeed,et al.  Comorbidity associated with atrial fibrillation: a general practice-based study. , 2001, The British journal of general practice : the journal of the Royal College of General Practitioners.

[85]  W. G. Breukink-Engbers.  Monitoring therapy with anticoagulants in The Netherlands. , 1999, Seminars in thrombosis and hemostasis.

[86]  S. Thompson,et al.  Factors affecting the maintenance dose of warfarin. , 1992, Journal of clinical pathology.